Female Factor
FMR1 / POI
Fragile-X changes linked to early loss of ovarian function.
Sizes FMR1 CGG repeats; the premutation range is linked to fragile-X-associated ovarian insufficiency.
- Specimen
- EDTA blood
- Methodology
- PCR ± Southern blot (CGG repeat sizing)
- Category
- Female Factor
Pricing is available through your BioBloom portal or on request.
How it works
- 1
Order
Place the order through the BioBloom portal.
- 2
Sample
Collect the sample — EDTA blood.
- 3
Analysis
Laboratory analysis — PCR ± Southern blot (CGG repeat sizing).
- 4
Report
Secure report delivered to your clinic through the portal.
What’s in the report
FMR1 CGG repeat size and category (normal / intermediate / premutation / full).
Research & evidence
Well-establishedFemale factor
Karyotyping and FMR1 (fragile-X) premutation testing are guideline-recommended parts of the premature-ovarian-insufficiency and reduced-ovarian-reserve workup.
Limitations: These tests identify risk factors, not certainties. The FMR1 premutation is incompletely penetrant: it raises the risk of ovarian insufficiency but does not predict whether or when it will occur.
Read the research
